Valion Bio, Inc. (VBIO) stock
VBIONasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.53+0.02 (+4.05%)
Close on Nov 13, 2026Market cap $2.20MP/E –Yield –
Valion Bio operating margin
Operating margin is operating income as a percentage of revenue.
Valion Bio's operating margin for the twelve months ending Sep 30, 2025 was -1210.8%. For fiscal 2024 it was -573.8%, against -701.1% the year before.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2024 | Dec 31, 2024 | -573.8% | +127.3 |
| FY2023 | Dec 31, 2023 | -701.1% | −152.3 |
| FY2022 | Dec 31, 2022 | -548.8% | −100.7 |
| FY2021 | Dec 31, 2021 | -448.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2025 | Sep 30, 2025 | -1700.7% | −565.0 |
| Q2 FY2025 | Jun 30, 2025 | -1951.2% | −1046.9 |
| Q1 FY2025 | Mar 31, 2025 | -1967.1% | −1523.7 |
| Q4 FY2024 | Dec 31, 2024 | -165.6% | +463.0 |
| Q3 FY2024 | Sep 30, 2024 | -1135.7% | −511.6 |
| Q2 FY2024 | Jun 30, 2024 | -904.3% | +415.6 |
| Q1 FY2024 | Mar 31, 2024 | -443.4% | +119.4 |
| Q4 FY2023 | Dec 31, 2023 | -628.6% | −75.6 |
| Q3 FY2023 | Sep 30, 2023 | -624.1% | −82.4 |
| Q2 FY2023 | Jun 30, 2023 | -1319.9% | −748.3 |
| Q1 FY2023 | Mar 31, 2023 | -562.8% | −39.2 |
| Q4 FY2022 | Dec 31, 2022 | -552.9% | +36.3 |
| Q3 FY2022 | Sep 30, 2022 | -541.7% | −98.0 |
| Q2 FY2022 | Jun 30, 2022 | -571.6% | −177.9 |
| Q1 FY2022 | Mar 31, 2022 | -523.6% | −196.4 |
| Q4 FY2021 | Dec 31, 2021 | -589.2% | – |
| Q3 FY2021 | Sep 30, 2021 | -443.7% | – |
| Q2 FY2021 | Jun 30, 2021 | -393.7% | – |
| Q1 FY2021 | Mar 31, 2021 | -327.2% | – |
See a number that looks wrong?